Leadership Overview
AbbVie has 10 executives leading key functions including corporate strategy, international operations, neuroscience research, clinical development, oncology insights, data science, financial integration, revenue partnerships, medical affairs, and financial management.
Committed to advancing global health through scientific innovation, AbbVie delivers transformative medicines that address complex medical challenges while improving patient outcomes across immunology, oncology, and neuroscience.
Committed to advancing global health through scientific innovation, AbbVie delivers transformative medicines that address complex medical challenges while improving patient outcomes across immunology, oncology, and neuroscience.
Leadership Roles at AbbVie
Hasan Kurt - Chief Financial Officer, Integration Lead Allergan Aesthetics
Hasan Kurt, the Chief Financial Officer, Integration Lead Allergan Aesthetics at AbbVie, manages the financial synergy between the core business and the medical aesthetics division. Overseeing the integration of financial systems, the Chief Financial Officer, Integration Lead Allergan Aesthetics ensures that the aesthetics portfolio contributes effectively to the overall corporate revenue strategy. Hasan Kurt directs fiscal planning and resource allocation to support the expansion of medical aesthetics products in global markets. By aligning financial reporting with operational goals, the Chief Financial Officer, Integration Lead Allergan Aesthetics maintains transparency and fiscal health across the division. This role requires constant coordination with executive leadership to monitor the financial performance of the aesthetics business. Through strategic financial management, Kurt secures the capital necessary for continued innovation in the aesthetics space. The Chief Financial Officer, Integration Lead Allergan Aesthetics drives profitability, ensuring that the division remains a key component of the company long-term growth strategy.
Pinar Ceylan - Director, Finance & Chief Financial Officer
Pinar Ceylan, the Director, Finance & Chief Financial Officer at AbbVie, manages the fiscal health and financial planning for the organization. Overseeing budgeting, forecasting, and capital allocation, the Director, Finance & Chief Financial Officer ensures that the company maintains the financial strength required to fund ongoing research and development. Pinar Ceylan directs financial reporting processes to provide transparency to stakeholders and the Board. By analyzing economic trends and operational costs, the Director, Finance & Chief Financial Officer optimizes resource distribution across all therapeutic areas. This role involves constant collaboration with other C-suite leaders to align financial strategies with the company mission of delivering innovative health solutions. Through rigorous financial oversight, Ceylan supports the long-term sustainability of the business. The Director, Finance & Chief Financial Officer drives fiscal discipline, ensuring that the company possesses the necessary capital to address complex medical challenges and improve patient outcomes globally.
Portia Chen - Chief of Staff
Portia Chen, the Chief of Staff at AbbVie, coordinates executive workflows to ensure alignment with the biopharmaceutical mission. Managing high-level administrative priorities, the Chief of Staff facilitates communication between leadership teams to accelerate the development of innovative health solutions. Portia Chen optimizes internal processes, allowing the organization to focus resources on complex medical challenges within immunology and neuroscience. By streamlining decision-making frameworks, the Chief of Staff supports the broader corporate objective of delivering life-altering therapies to patients globally. This role requires constant interaction with department heads to maintain operational efficiency across the North Chicago headquarters and international sites. Through rigorous oversight of strategic initiatives, Chen ensures that every project remains tethered to the core goal of improving patient quality of life. The Chief of Staff maintains a clear vision for organizational excellence, driving performance metrics that define the success of the entire enterprise.
Megan Kehl - Head of International Strategic Operations Chief of Staff
Megan Kehl, the Head of International Strategic Operations Chief of Staff at AbbVie, directs cross-border initiatives to expand the reach of life-saving pharmaceutical products. Overseeing international market penetration, the Head of International Strategic Operations Chief of Staff aligns regional commercial efforts with global research goals. Megan Kehl manages complex logistics and regulatory landscapes to ensure consistent delivery of medical solutions across diverse territories. By integrating strategic operations with local market needs, the Head of International Strategic Operations Chief of Staff maximizes the impact of the company portfolio in neuroscience and oncology. This leadership position requires constant collaboration with global stakeholders to refine supply chains and distribution networks. Through meticulous planning, Kehl secures the operational stability necessary for sustained growth in competitive international markets. The Head of International Strategic Operations Chief of Staff drives efficiency, ensuring that every regional strategy supports the overarching mission of addressing unmet medical needs on a global scale.
Martin Hayes - Global Neuroscience & Ophthalmology Research Chief of Staff
Martin Hayes, the Global Neuroscience & Ophthalmology Research Chief of Staff at AbbVie, manages the scientific pipeline for critical therapeutic areas. Coordinating research teams, the Global Neuroscience & Ophthalmology Research Chief of Staff accelerates the discovery of treatments for chronic and serious neurological conditions. Martin Hayes bridges the gap between laboratory innovation and clinical application, ensuring that research efforts remain focused on high-impact patient outcomes. By overseeing resource allocation for ophthalmology and neuroscience projects, the Global Neuroscience & Ophthalmology Research Chief of Staff maintains a competitive edge in the biopharmaceutical sector. This role involves frequent coordination with the Board to present data-driven progress reports on drug development milestones. Through strategic oversight, Hayes ensures that scientific breakthroughs translate into viable health solutions. The Global Neuroscience & Ophthalmology Research Chief of Staff drives the research agenda, fostering an environment where complex medical challenges receive the necessary attention to yield meaningful therapeutic advancements.
Brian Szopinski - Director, Clinical Operations & Chief of Staff
Brian Szopinski, the Director, Clinical Operations & Chief of Staff at AbbVie, manages the execution of complex clinical trials across the global portfolio. Overseeing the operational infrastructure for drug testing, the Director, Clinical Operations & Chief of Staff ensures compliance with international regulatory standards. Brian Szopinski coordinates with research scientists and medical teams to optimize trial timelines and data collection processes. By refining clinical workflows, the Director, Clinical Operations & Chief of Staff accelerates the path from discovery to patient access for new medicines. This leadership role requires constant monitoring of trial performance metrics to ensure that every study meets the rigorous quality benchmarks set by the company. Through effective management of clinical resources, Szopinski supports the development of therapies in immunology and oncology. The Director, Clinical Operations & Chief of Staff drives operational excellence, ensuring that clinical operations remain a cornerstone of the company commitment to delivering innovative health solutions.
Valerie Menaker - Director II, Business Strategy and Insights and Chief of Staff, Oncology Early Development
Valerie Menaker, the Director II, Business Strategy and Insights and Chief of Staff, Oncology Early Development at AbbVie, architects the strategic roadmap for the oncology pipeline. Analyzing market trends and clinical data, the Director II, Business Strategy and Insights and Chief of Staff, Oncology Early Development identifies opportunities for growth in early-stage cancer research. Valerie Menaker integrates business insights with scientific development to ensure that the company invests in the most promising therapeutic candidates. By collaborating with research and commercial teams, the Director II, Business Strategy and Insights and Chief of Staff, Oncology Early Development aligns development goals with long-term market needs. This role requires deep analytical rigor to forecast the potential impact of new oncology treatments. Through strategic planning, Menaker ensures that the early development phase remains robust and focused on addressing significant unmet medical needs. The Director II, Business Strategy and Insights and Chief of Staff, Oncology Early Development drives innovation, securing the future of the oncology portfolio.
Mark Schacher - Director, Data and Statistical Science and Chief of Staff
Mark Schacher, the Director, Data and Statistical Science and Chief of Staff at AbbVie, leads the analytical framework supporting drug development and clinical research. Overseeing the application of statistical models, the Director, Data and Statistical Science and Chief of Staff ensures the integrity and accuracy of clinical trial data. Mark Schacher directs teams of data scientists to extract actionable insights that inform critical research decisions. By leveraging advanced analytics, the Director, Data and Statistical Science and Chief of Staff optimizes the development process for new medicines in neuroscience and immunology. This role involves constant collaboration with clinical operations to validate findings and support regulatory submissions. Through technical leadership, Schacher ensures that data-driven evidence remains the foundation of the company scientific efforts. The Director, Data and Statistical Science and Chief of Staff drives innovation in data management, ensuring that complex medical challenges are addressed with precision and scientific rigor.
Carrianne Ludwig - Director of Chief Revenue Officer and Vendor Partnerships, Oncology Early Development
Carrianne Ludwig, the Director of Chief Revenue Officer and Vendor Partnerships, Oncology Early Development at AbbVie, manages external collaborations to accelerate oncology research. Overseeing vendor relationships, the Director of Chief Revenue Officer and Vendor Partnerships, Oncology Early Development ensures that the company accesses the best external expertise and technology for early-stage cancer drug development. Carrianne Ludwig coordinates with the Chief Revenue Officer to align partnership strategies with commercial objectives. By optimizing these vendor networks, the Director of Chief Revenue Officer and Vendor Partnerships, Oncology Early Development reduces development timelines and enhances the efficiency of the oncology pipeline. This role requires constant negotiation and management of complex service agreements to support the research mission. Through strategic partnership oversight, Ludwig ensures that the company maintains a competitive advantage in the oncology sector. The Director of Chief Revenue Officer and Vendor Partnerships, Oncology Early Development drives operational success, ensuring that external resources effectively support the development of life-altering cancer therapies.
Yutaka Nakao - Medical Chief of Staff (Japan)
Yutaka Nakao, the Medical Chief of Staff (Japan) at AbbVie, directs medical affairs and clinical strategy within the Japanese market. Overseeing the implementation of medical programs, the Medical Chief of Staff (Japan) ensures that healthcare providers receive accurate information regarding the company portfolio of innovative medicines. Yutaka Nakao coordinates with local regulatory bodies and medical experts to facilitate the adoption of new therapies in immunology and neuroscience. By aligning medical strategy with regional health needs, the Medical Chief of Staff (Japan) enhances the company presence in the Japanese pharmaceutical landscape. This role requires constant engagement with the medical community to address unmet patient needs and improve health outcomes. Through strategic leadership, Nakao ensures that the company medical initiatives in Japan remain consistent with global standards. The Medical Chief of Staff (Japan) drives medical excellence, ensuring that the company remains a trusted partner in the Japanese healthcare system.
Explore Leadership Teams in Manufacturing
Since 2006, Pharos Indonesia has been the fastest growing pharmaceutical company in Indonesia, achieving 40% annual growth. In 2009, based on IMS* reports, Pharos became the 4th largest Indonesian pharmaceutical company; jumping from position 12 in just 4 years. Pharos marketing teams have forged strong relationships with major hospital groups as well as individual doctors, including specialists and this ensures strong distribution of our products. No other pharmaceutical manufacturer, nor retail pharmacy group, can compete with the strength of the Pharos-controlled network of almost 2,000 pharmacies spread across Indonesia. Pharos is uniquely positioned to take advantage of the large and fast-growing ASEAN region.
Company Leadership VP
HD
AL
RR
21st Century Vitamins operates as a globally recognized manufacturer and distributor of dietary supplements, positioned within the broader health and wellness industry. The company, through its parent entity 21st Century HealthCare, Inc., focuses on developing, producing, and delivering a wide range of vitamins, minerals, herbal supplements, and specialty nutritional products designed to support everyday health and well-being. With a history spanning more than three decades, the organization has established itself as a trusted and accessible brand in the consumer healthcare market. At its core, the company functions as both a manufacturer and a direct-to-consumer wellness provider. It produces an extensive portfolio of dietary supplements that cater to diverse health needs, including general nutrition, immune support, cardiovascular health, digestive wellness, sports nutrition, and beauty supplements. Its offerings range from traditional multivitamins and single-nutrient formulations to advanced blends such as amino acids, probiotics, and plant-based supplements. This breadth of product categories reflects the companys strategy of addressing a wide spectrum of consumer health requirements through scientifically formulated solutions.
Company Leadership SS
KW
FC
Founded in 1987, Integrated DNA Technologies, Inc. headquartered in Coralville, Iowa, is the supplier of custom nucleic acids, serving the areas of academic research, biotechnology, clinical diagnostics, and pharmaceutical development. The company develops, manufactures, and markets nucleic acid products for the life sciences industry.
Company Leadership AA
MM
AM
CL
Formosa Laboratories, Inc. produces APIs and UV-filters in its modern facilities near Taipei. Its GMP compliance has been approved by DOH of Taiwan, US FDA, BGV of Germany, EDQM and PMDA of Japan. Formosas major API products include Vitamin D derivatives (Alfacalcidol, Calcitriol, Calcipotriol, Doxercalciferol, and Paricalcitol), Balsalazide, Benzonatate, Capsaicin, Colesevelam, Gadodiamide, Flupentixol, Melitracen, Meprobamate, Montelukast, Mycophenolate Mofetil, Sevelamer (HCl and Carbonate), and Taltirelin. As a major producer in the world, the company's UV-filter products include avobenzone and Octinoxate. The company also provide custom synthesis service from process development to full commercial production for APIs and other specialty chemicals, with full documentation support.
Company Leadership CY
CC
CC
CY
Frequently Asked Questions Regarding AbbVie Top Executives and Leadership Team
Unlock more people and company data
